Skip to main content

Table 1 Patients’ characteristics (n = 5,562)

From: Hepatitis C treatment initiation in HIV-HCV coinfected patients

Characteristic  
Male, n (%) 3976 (71.5 %)
Age (year), median (IQR) 39 (35–43)
HIV risk factor, n (%)  
 Intravenous drug use 3330 (59.9 %)
 Hemophilia, transfusion, nosocomial 310 (5.6 %)
 Heterosexual contact 990 (17.8 %)
 Men having sex with men 731 (13.1 %)
 Other, unknown 201 (3.6 %)
Known duration of HIV infection (year), median (IQR) 11 (5–14)
CDC stage, n (%)  
 Stage A 2731 (49.1 %)
 Stage B 1204 (21.6 %)
 Stage C 1626 (29.2 %)
Under cART at entry, n (%) 3554 (63.9 %)
Under cART during follow up, n (%) 1648 (29.6 %)
cART naive, n (%) 360 (6.5 %)
Deceased 748 (13.4 %)
Known duration of HCV infection (year), median (IQR) 2 (0–7)
HCV risk factor, n (%)  
 Intravenous drug use 3588 (64.5 %)
 Hemophilia, transfusion, nosocomial 339 (6.1 %)
 Sexual 580 (10.4 %)
 Other, unknown 1055 (19.0 %)
HCV genotype information available  
 All cohort 3137 (56.4 %)
 Patient not spontaneously cured 3086 (59.4 %)
HCV genotype  
 Genotype 1 1676 (53.4 %)
 Genotype 2 99 (3.2 %)
 Genotype 3 763 (24.3 %)
 Genotype 4 584 (18.6 %)
 Genotype 5 4 (0.1 %)
 Genotype 6 4 (0.1 %)
Fibrosis evaluation, n (%) 2869 (51.6 %)
  1. cART combination antiretroviral therapy, CDC Centers for Disease Control and Prevention, HCV hepatitis C virus, HIV human immunodeficiency virus, IQR interquartile range, SVR sustained virological response